SIRI-PGC-1 pathways are recognized as interesting targets for NAFLD because they are involved in lipid metabolism, mitochondrial activation and inflammation in liver [20,21]. This evidence concerns the gene PPARGC1A and metabolic dysfunction-associated steatotic liver disease.